Objetivos:
To assess, compare and correlate:
1) the systemic inflammatory and proresolving profiles;
2) endothelial activation/dysfunction and coagulation status;
3) oxidative stress/oxidative damage;
4) RAAS activity in ICU COVID-19 patients, non-ICU COVID-19 patients and healthy controls, to identify risk stratification biomarkers and putative therapeutic targets to prevent and counteract the development of cytokine storm and multiorgan damage caused by COVID-19.
Resultados esperados:
1) Impaired resolution of inflammation (reduced values of SPMs), enhanced endothelial activation and coagulation, augmented oxidative damage and marked RAAS activation in severe COVID-19 patients.
2) Demonstration of endocan usefulness as a tool for the prediction of ARDS development, severity and mortality in COVID-19 patients. |